OBIO vs. NPCE, SMLR, TMCI, CLPT, OM, NNOX, NYXH, SMTI, ZIMV, and STIM
Should you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include NeuroPace (NPCE), Semler Scientific (SMLR), Treace Medical Concepts (TMCI), ClearPoint Neuro (CLPT), Outset Medical (OM), Nano-X Imaging (NNOX), Nyxoah (NYXH), Sanara MedTech (SMTI), ZimVie (ZIMV), and Neuronetics (STIM). These companies are all part of the "medical equipment" industry.
Orchestra BioMed vs. Its Competitors
NeuroPace (NASDAQ:NPCE) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.
NeuroPace has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.
78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 53.5% of Orchestra BioMed shares are owned by institutional investors. 22.2% of NeuroPace shares are owned by insiders. Comparatively, 8.1% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
NeuroPace has a net margin of -36.74% compared to Orchestra BioMed's net margin of -2,179.33%. Orchestra BioMed's return on equity of -107.04% beat NeuroPace's return on equity.
NeuroPace received 13 more outperform votes than Orchestra BioMed when rated by MarketBeat users. However, 100.00% of users gave Orchestra BioMed an outperform vote while only 62.96% of users gave NeuroPace an outperform vote.
NeuroPace currently has a consensus price target of $15.50, suggesting a potential upside of 38.02%. Orchestra BioMed has a consensus price target of $14.20, suggesting a potential upside of 349.37%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than NeuroPace.
NeuroPace has higher revenue and earnings than Orchestra BioMed. NeuroPace is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
In the previous week, NeuroPace had 14 more articles in the media than Orchestra BioMed. MarketBeat recorded 15 mentions for NeuroPace and 1 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 1.89 beat NeuroPace's score of 0.48 indicating that Orchestra BioMed is being referred to more favorably in the news media.
Summary
NeuroPace beats Orchestra BioMed on 11 of the 19 factors compared between the two stocks.
Get Orchestra BioMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orchestra BioMed Competitors List
Related Companies and Tools
This page (NASDAQ:OBIO) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy OBIO Stock Free OBIO Stock Alerts